Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
Zebra Technologies reports strong Q3 results, but margins decline and guidance raises concerns about execution and the company's shift to software and services.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
Zebra Technologies reports strong Q3 results, but margins decline and guidance raises concerns about execution and the company's shift to software and services.